

Technology Advisory Committee B Interests Register

Topic: Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]

Publication Date: 28/06/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Nick Latimer	TAC Committee Member	Non-Financial professional and personal interest	Professor Latimer is a member of the SchARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme (MSD). This is not drug or appraisal specific and is about developing methods. MSD are listed as a comparator company.	14/12/2022	It was agreed that his declaration would not prevent Professor Latimer from participating in discussions on this appraisal.
Professor David McAllister	TAC Committee Member	Non-financial professional and personal interest	Professor McAllister performs secondary analysis of trial data which was provided by sponsors (or their competitors) via the Vivli, CSDR and YODA trial platforms.	14/12/2022	It was agreed that his declaration would not prevent Professor McAllister from participating in discussions on this appraisal.
Peter Wheatley-Price	TAC Committee Member	Direct financial interest	Peter Wheatley-Price's as his organisation, Takeda have Soticlestat, (TAK-935) in phase III trials to treat rare developmental and epileptic encephalopathies (DEE) including Dravet syndrome and	14/12/2022	It was agreed that his declaration would not prevent Peter Wheatley-Price from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Lennox-Gastaut Syndrome. Soticlestat will be a direct competitor to cannabidiol in Dravet & LGS, to his knowledge there are no investigational trials in this specific indication.		discussions on this appraisal.
Helen McAteer	Patient Expert	Indirect financial interest	Helen McAteer's organisation, Psoriasis Association has received core fundings from Bristol Myers Squibb and comparator manufacturers such as Abbvie, Almiral, Amgen, Eli Lilly, Janssen, LEO Pharma, Novartis, and UCB.	14/12/2022	It was agreed that her declaration would not prevent Helen McAteer from providing expert advice to the committee.
Dr Kave Shams	Clinical Expert	Direct financial interest	Dr Kave Shams has received honoraria for advisory boards and educational provision aswell as research funding from AbbVie, Almirall, Celgene, Eli Lilly, Janssen, Novartis, Amgen, Biogen, UCB, Boehringer-Ingelheim and Sandoz. Dr Kave Shams is also an investigator for Abbvie, Novartis, UCB, BMS, Janssen, Celgene.	14/12/2022	It was agreed that his declaration would not prevent Dr Kave Shams from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David Chandler	Patient Expert	Non-financial professional and personal interest	David Chandler was a previous member of a NICE Technology Appraisal Committee and is currently a member of the NICE Appeals Committee.	14/12/2022	It was agreed that his declaration would not prevent David Chandler from providing expert advice to the committee.